

# Yuxuan Liu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9301114/publications.pdf>

Version: 2024-02-01

16  
papers

354  
citations

1163117

8  
h-index

1058476

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

867  
citing authors

#	ARTICLE	IF	CITATIONS
1	The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component. <i>Seminars in Cancer Biology</i> , 2014, 24, 15-22.	9.6	102
2	Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. <i>Clinical Cancer Research</i> , 2019, 25, 5271-5283.	7.0	59
3	NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12034-12039.	7.1	41
4	IgG gene expression and its possible significance in prostate cancers. <i>Prostate</i> , 2012, 72, 690-701.	2.3	35
5	Immunoglobulin G (IgG) Expression in Human Umbilical Cord Endothelial Cells. <i>Journal of Histochemistry and Cytochemistry</i> , 2011, 59, 474-488.	2.5	31
6	BET Inhibition-Induced GSK3 $\beta$ Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. <i>Cell Reports</i> , 2018, 24, 2155-2166.	6.4	31
7	Transcription Factors E2A, FOXO1 and FOXP1 Regulate Recombination Activating Gene Expression in Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e20475.	2.5	22
8	Immunoglobulin G Locus Events in Soft Tissue Sarcoma Cell Lines. <i>PLoS ONE</i> , 2011, 6, e21276.	2.5	10
9	PML Nuclear Bodies and SATB1 Are Associated with HLA Class I Expression in EBV+ Hodgkin Lymphoma. <i>PLoS ONE</i> , 2013, 8, e72930.	2.5	5
10	Hypomethylating Agents in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2020, 21, 61.	3.0	5
11	Chromatin-Remodeled State in Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 439-450.	2.3	4
12	Epigenetic Targeting with EZH2 and HDAC Inhibitors Is Synergistic in EZH2 Deregulated Lymphomas. <i>Blood</i> , 2016, 128, 839-839.	1.4	4
13	Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators. <i>Blood</i> , 2019, 134, 4068-4068.	1.4	3
14	Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma. <i>Blood</i> , 2018, 132, 37-37.	1.4	2
15	MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 294-294.	1.4	0
16	A basal gene expression signature to predict for synergy of combined EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7546-7546.	1.6	0